Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa study of MG-K10 in adolescents with moderate-to-severe atopic dermatitis
CTR20242412Phase 2Completed
- Sponsor
- Medigene AG
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of comekibart in atopic dermatitis (AD), sponsored by Medigene AG. Started Jul 2024; status: completed.
02
Drugs
comekibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20242412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242412.